Friday, January 30, 2015 2:20:44 PM
NNVC paid 6 figures to make the Yidam suit go away.
As for the class action suits, I'm guessing due to Stockholm Syndrome fuel of the cult wished to sue those that cost them thousands upon thousands of dollars -- they instead sympathize with NNVC management.
Even total scams that go completely bust sometimes have trouble gathering enough interest for a class action suit. Some people take responsibility for their own lousy investment decisions I suppose. I'm one of those -- I don't ever join class action suits. Good for NNVC shareholders who likewise choose that route though I suspect for many of them it has more to do with the aforementioned Stockholm Syndrome. You know -- where the victims sympathize with their captors then actually willingly participate and defend them. Kind of like defending Seymour's buy more at $5.70 emails.
As for the class action suits, I'm guessing due to Stockholm Syndrome fuel of the cult wished to sue those that cost them thousands upon thousands of dollars -- they instead sympathize with NNVC management.
Even total scams that go completely bust sometimes have trouble gathering enough interest for a class action suit. Some people take responsibility for their own lousy investment decisions I suppose. I'm one of those -- I don't ever join class action suits. Good for NNVC shareholders who likewise choose that route though I suspect for many of them it has more to do with the aforementioned Stockholm Syndrome. You know -- where the victims sympathize with their captors then actually willingly participate and defend them. Kind of like defending Seymour's buy more at $5.70 emails.
The SwingTrade Portfolio is up 5.8% YTD through 01/27/15, 36.2% in 2014, 83.5% in 2013, and 546.6% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110307454
Recent NNVC News
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2025 09:07:54 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/29/2025 08:33:17 PM
